The global atrial fibrillation treatment devices market is projected to grow from $9.6 billion in 2026 to $29.0 billion by 2035, a 13.1% compound annual growth rate, according to a 219-page ResearchAndMarkets.com report added to its offering on Aug. 26, 2026. Growth is being supported by atrial fibrillation prevalence, population aging, rising procedure volumes, regulatory activity and adoption of advanced ablation and left atrial appendage closure technologies. The condition affects an estimated 50 million to 60 million people worldwide, with prevalence rising from about 6.4% among people aged 65-69 to 28.5% among those aged 85 and older. Ablation catheters are expected to generate about 75% of market revenue, while the left atrial appendage closure segment is forecast to grow at a 13.4% CAGR through 2035. Pulsed field ablation is projected to account for more than 60% of revenue by 2035. North America is expected to retain close to 50% of global revenue, while Asia-Pacific is forecast to be the fastest-growing region. The report identifies Abbott, AtriCure, Boston Scientific, Johnson & Johnson and Medtronic as prominent participants, while citing reimbursement gaps, clinical complexity, infrastructure requirements and limited long-term durability data as adoption challenges.